Table 1 Baseline clinical characteristics.

From: Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Patient characteristics (N = 21)

DCB (N = 9)

NDB (N = 12)

Age (years), median (range)

64 (58–79)

64 (46–71)

Gender

Male

7 (78%)

8 (67%)

Female

2 (22%)

4 (33%)

Histology

Non-squamous

7 (78%)

5 (42%)

Squamous

2 (22%)

7 (58%)

Smoking status

Current/former

7 (78%)

9 (75%)

Never

2 (22%)

3 (25%)

Stage

IIIB

3 (33%)

4 (33%)

IV

6 (67%)

8 (67%)

PD-L1 expression

0%

2 (22%)

4 (33%)

1–50%

4 (44%)

5 (42%)

≥50%

3 (33%)

3 (25%)

Genotypes

EGFR mutation

0

1 (1%)

ALK fusion

0

0

Prior systemic therapy

1

5 (50%)

5 (46%)

2

2 (20%)

2 (18%)

3

1 (10%)

2 (18%)

≥4

1 (10%)

2 (18%)

Back to article page